ProMIS Neurosciences (PMN) Other Non-Current Liabilities (2021 - 2025)
ProMIS Neurosciences' (PMN) quarterly Other Non-Current Liabilities came in at $29182.0 in Q4 2025, up 421.85% YoY from $5592.0 in Q4 2024, and up 421.85% on a QoQ basis from $5592.0 in Q3 2025.
ProMIS Neurosciences (PMN) Other Non-Current Liabilities (2021 - 2025) Analysis & Trends
ProMIS Neurosciences (PMN) has 5 years of Other Non-Current Liabilities data on file, last reported at $29182.0 in Q4 2025.
- Quarterly Other Non-Current Liabilities rose 421.85% year-over-year to $29182.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29182.0 (up 421.85% YoY) and the FY2025 annual result came in at $29182.0, up 421.85% from the prior year.
- Other Non-Current Liabilities grew to $29182.0 in Q4 2025, from $5592.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $14.3 million in Q3 2024 to a low of $5592.0 in Q4 2024.
- A 5-year average of $1.8 million and a median of $192837.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities jumped 5042.18% — and 2025, when it sank 99.96%.
- Tracing PMN's Other Non-Current Liabilities over 5 years: stood at $5.4 million in 2021, then tumbled by 65.44% to $1.9 million in 2022, then plunged by 94.93% to $94185.0 in 2023, then tumbled by 94.06% to $5592.0 in 2024, then jumped by 421.85% to $29182.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $29182.0 (Q4 2025), $5592.0 (Q3 2025), and $5592.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29,182.00 |
| Sep 30, 2025 | 5,592.00 |
| Jun 30, 2025 | 5,592.00 |
| Mar 31, 2025 | 5,592.00 |
| Dec 31, 2024 | 5,592.00 |
| Sep 30, 2024 | 14.26 Mn |
| Jun 30, 2024 | 49,231.00 |
| Mar 31, 2024 | 108,318.00 |
| Dec 31, 2023 | 94,185.00 |
| Sep 30, 2023 | 277,356.00 |
| Jun 30, 2023 | 1.29 Mn |
| Mar 31, 2023 | 1.90 Mn |
| Dec 31, 2022 | 1.86 Mn |
| Sep 30, 2022 | 1.55 Mn |
| Jun 30, 2022 | 1.61 Mn |
| Dec 31, 2021 | 5.38 Mn |